Monthly Archives: August 2018


The University of Victoria hosts a successful 34th annual meeting of the Canadian Society for Biomaterials

2018-08-15T00:00:00-07:00August 15th, 2018|Categories: News, Newsletter, Trainee Steering Committee|

Dr. Stephanie M. Willerth, conference chair and the 2017-18 President of the Canadian Biomaterials Society (CBS), along with her organizing committee hosted the 34th Annual Meeting of CBS at the University of Victoria during May 16th through 19th. The meeting consisted of a 4-day event attended by 135 people: 90 students, 5 researchers, 25 professors, 15 post-docs, and industry partners. During this meeting, the latest advances on research in the field of Biomaterials and Tissue engineering in Canada were shared and discussed. The event was supported by CBS and external industry funding; Aspect Biosystems as the Gold Sponsor, Rheolution as Silver [...]

Careers Column

2018-08-15T00:00:00-07:00August 15th, 2018|Categories: Newsletter, Trainee Steering Committee|

Welcome to the BCRGEGMED Blog's Quarterly Career Column! Here we will feature career profiles with scientific professionals in British Columbia. In this issue, we interviewed Dr. Vincenzo Macri, Senior Scientist, Myogenic Group, STEMCELL Technologies. Describe a typical day in your position? What are your day-to-day activities like? Working in Research and Development is great because every day can be different. My role as a Senior Scientist and Team Lead of the Myogenic Group involves short and long-term planning of product development, working with a talented team of researchers, reviewing and presenting data, keeping up to date on current research, and collaborating [...]

Tackling the world’s deadliest diseases one Ab at a time: An interview with AbCellera’s CEO, Dr. Carl Hansen

2018-08-14T00:00:00-07:00August 14th, 2018|Categories: News, Newsletter, Trainee Steering Committee|

Dr. Carl Hansen, CEO of AbCellera, a Vancouver-based biotech on the hunt for novel antibodies. Can one company simultaneously work on solving the problems of Ebola, influenza, neurodegeneration, cancer, tuberculosis, and enterotoxicogenic E. coli? If you are AbCellera, a Vancouver-based biotech on the hunt for novel antibodies that can be used to fight these diseases, the answer is yes. The company has built the world’s leading platform for the discovery of monoclonal antibodies and the profiling of natural immune responses. This proprietary platform, which uses a combination of microfluidics, genomics, microscopy, and machine learning, allows for screening millions of [...]

Go to Top